# The Use of Allogenic Platelet Rich Plasma for the Treatment of Diabetic Foot Ulcer

> **NCT02972528** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hanan Jafar** · enrollment: 30 (estimated)

## Conditions studied

- Diabetic Foot Ulcer

## Interventions

- **BIOLOGICAL:** Platelet Lysate
- **BIOLOGICAL:** Platelet Poor Plasma

## Key facts

- **NCT ID:** NCT02972528
- **Lead sponsor:** Hanan Jafar
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-03
- **Primary completion:** 2020-02
- **Final completion:** 2020-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02972528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02972528, "The Use of Allogenic Platelet Rich Plasma for the Treatment of Diabetic Foot Ulcer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02972528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*